Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness

Trial Profile

Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs Flecainide/modafinil (Primary)
  • Indications Sleep disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Theranexus
  • Most Recent Events

    • 16 Jul 2018 According to a Theranexus media release, results are expected by the end of first half of 2019.
    • 16 Jul 2018 Status changed from planning to recruiting, according to an Theranexus media release.
    • 16 Jul 2018 According to an Theranexus media release, first patient has been included in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top